NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Contract Research Orgs » VENTURE PHARM SERVICE--VPScro  1    
found files: 11
VENTURE PHARM SERVICE--VPScro »27/07/2007 [Company watch]
Raising HK$ 97 million-- VPS-CRO---- A Chinese Leader in Preclinical & Clinical Service Is Ready To Run

On 27 July 2007, the Company and a Swiss financial corporation, entered into the Note Purchase Agreement in respect of the issue of the Convertible Notes in the principal amount of CHF 15 million (approximately HK$ 97.2 million) due 2012....   more»


VENTURE PHARM SERVICE--VPScro »02/04/2008 [Company watch]
Commonwealth Forms Joint Venture with Venturepharm for Outsourcing Services

Commonwealth Biotechnologies, Inc. and Venturepharm Laboratories Ltd have formed a China-based joint venture that will provide a continuous spectrum of outsourcing services. The move came after Venturepharm bought a 39% stake in CBI. The 2.15 million block of shares, which had previously belonged to PharmAust Ltd., has a market value of $5.85 million. The China JV will be known as Venturepharm Asia. It will be the “shop front” for Venturepharm’s CRO services. The JV is unusual in that both contributing organizations are already publicly traded, but it follows a recent pattern of CROs in the west and the east forming alliances to provide a greater number of services in a geographically diversified manner. CBI will contribute early stage drug discovery technologies, business development, marketing and quality assurance services to the JV. Venturepharm will provide contract manufacturing and clinical trial services. Dr. Paul D'Sylva, CEO of CBI, noted that 60% of the $34 billion that life sciences companies spend on outsourcing went to contract manufacturing. Clinical research was the recipient of 33% of the total and 7% went to custom chemical synthesis. For CBI, the JV allows it to offer contract manufacturing and clinical trial management to clients who have used Commonwealth for its custom synthesis and other services. CBI now operates the following units: • CBI Services (Richmond, VA), a discovery phase contract research organization; • Fairfax Identity Laboratories, a DNA reference business; • Mimotopes Pty, Ltd (Melbourne, Australia), a peptide and discovery chemistry business; Exelgen, Ltd (Bude, UK), a medicinal and synthetic discovery chemistry business; • Venturepharm Asia (Beijing, China), process scale-up, formulation development, cGMP manufacturing and clinical trial management. CBI’s headquarters are in San Diego, while Venturepharm is based in Beijing. Venturepharm Laboratories Limited provides a large complement of drug discovery and development services that take new drugs from "idea to patients." These include API (Active Pharmaceutical Ingredient), formulation development, clinical trial management, product registration, marketing & sales to pharmaceutical and biotech companies in China and overseas....   more»


VENTURE PHARM SERVICE--VPScro »18/04/2008 [Company watch]
Commonwealth Biotechnologies, Inc. (CBTE) and Venturepharm Laboratories Ltd have formed a China-based joint venture

Commonwealth Biotechnologies, Inc. and Venturepharm Laboratories Ltd have formed a China-based joint venture that will provide a continuous spectrum of outsourcing services. The move came after Venturepharm bought a 39% stake in CBI. The 2.15 million block of shares, which had previously belonged to PharmAust Ltd., has a market value of $5.85 million. The China JV will be known as Venturepharm Asia. It will be the “shop front” for Venturepharm’s CRO services. The JV is unusual in that both contributing organizations are already publicly traded, but it follows a recent pattern of CROs in the west and the east forming alliances to provide a greater number of services in a geographically diversified manner. CBI will contribute early stage drug discovery technologies, business development, marketing and quality assurance services to the JV. Venturepharm will provide contract manufacturing and clinical trial services. Dr. Paul D'Sylva, CEO of CBI, noted that 60% of the $34 billion that life sciences companies spend on outsourcing went to contract manufacturing. Clinical research was the recipient of 33% of the total and 7% went to custom chemical synthesis. For CBI, the JV allows it to offer contract manufacturing and clinical trial management to clients who have used Commonwealth for its custom synthesis and other services. CBI now operates the following units: • CBI Services (Richmond, VA), a discovery phase contract research organization; • Fairfax Identity Laboratories, a DNA reference business; • Mimotopes Pty, Ltd (Melbourne, Australia), a peptide and discovery chemistry business; Exelgen, Ltd (Bude, UK), a medicinal and synthetic discovery chemistry business; • Venturepharm Asia (Beijing, China), process scale-up, formulation development, cGMP manufacturing and clinical trial management. CBI’s headquarters are in San Diego, while Venturepharm is based in Beijing. Venturepharm Laboratories Limited provides a large complement of drug discovery and development services that take new drugs from "idea to patients." These include API (Active Pharmaceutical Ingredient), formulation development, clinical trial management, product registration, marketing & sales to pharmaceutical and biotech companies in China and overseas....   more»


VENTURE PHARM SERVICE--VPScro »13/07/2008 [Company watch]
Commonwealth Biotech Invests in Venturepharm JV

Commonwealth Biotechnologies (CBTE) and Venturepharm Laboratories tightened up their relationship as Commonwealth exercised a $1 million put option with Venturepharm. Under the terms of the deal, Commonwealth sold 463,426 shares of common stock to Venturepharm at $2.15 per share, a 56% premium to the June 30, 2008 share price of $1.38. CBI received $500,000 in cash and 2.22 million shares of Venturepharm Holdings [HKEX: 8225], the parent of Venturepharm Labs. The shares are also worth $500,000. Commonwealth said it would use the proceeds in Venturepharm Asia, the joint venture formed between the two companies. The JV recently procured two preclinical chemistry facilities in China that Commonwealth will use to house and expand the operations of Exelgen and Mimotopes, its small molecule and peptide subsidiaries. Operations will begin in the new facilities in Q3. Dr. Paul D'Sylva, CEO of Commonweath, said the new facilities will provide cost and capacity advantages and that they will also offer potential for growth. The rationale behind the JV was that Commonwealth would contribute its expertise with early stage drug discovery technologies, business development, marketing and quality assurance services. Venturepharm would provide contract manufacturing and clinical trial services. Commonwealth operates through five business units: (1) CBI Services, a discovery-phase contract research organization; (2) Fairfax Identity Laboratories, a DNA reference business; (3) Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business; (4) Exelgen Ltd, Bude, UK, a medicinal and synthetic discovery chemistry business; and (5) Venturepharm Asia, Beijing, China, a contract research joint venture specializing in process scale-up, formulation development, cGMP manufacturing and clinical trial management. The parent of Venturepharm Labs, Venturepharm Holdings Limited, specializes in API formulation development, clinical trial management, product registration, and marketing & sales to pharmaceutical and biotech companies in China and overseas....   more»


VENTURE PHARM SERVICE--VPScro »26/08/2008 [Company watch]
Acesys Pharmatech Joins to Power Exelgen’s Drug Discovery in China

Venturepharm is delighted to announce that Acesys Pharmatech now becomes part of Venturepharm group to form the Chemical Drug Discovery (CMC) Division of Venturepharm Asia and provide help to Exelgen's operation in China. Acesys Pharmatech is a Nanjing based global drug discovery service company with around 70 chemists....   more»


VENTURE PHARM SERVICE--VPScro »26/08/2008 [Company watch]
Venturepharm Group and the State Genetic Engineering Drug Research Center reached strategic cooperation

Recently, Venturepharm group and the State Genetic Engineering Drug Research Center have reached an all-around strategic cooperation. The research center is the only state engineering research center at the state level officially approved by the National Development and Reform Commission. The two sides will take this opportunity to leverage the advantages of both sides to promote the R & D of genetic engineering drugs and provide more competitive service and products. It further strengthens the R & D capability of Venturepharm group....   more»


VENTURE PHARM SERVICE--VPScro »26/08/2008 [Company watch]
Venturepharm and Lorus Therapeutics forms alliance

Venturepharm group announced today that a new global Oncology platform will be created between Venturepharm and Lorus Therapeutics (LOR, LRP), a Canadian biotech with a strong Oncology pipeline of over 7 molecules in various stages of development. The platform will build a most sustainable & innovative Oncology business model and greatly reduce cost and produce a new generation of cancer treatment drug through leveraging on both parties’ Oncology expertise in preclinical research, clinical trials, etc. The service platform is expected to bring Venturepharm one step further to be the No.1 service provider for world oncology drug development with US/European Standard/Quality, but China local cost....   more»


VENTURE PHARM SERVICE--VPScro »26/08/2008 [Company watch]
Venturepharm still stands No.1 in New Drug Application in the first half year

According to the statistics from China SFDA, Venturepharm remains No.1 in New Drug Application in the first half year. The Group has initiated 10 new projects in the first half year of 2008 and till now has 238 products under development. The Group has totally submitted 226 patent applications. During the period, SFDA has granted 7 new Clinical Study Permits (“CSP”) and 16 new Manufacturing Permits (“MP”) to the Group. The total number of CSPs has reached 300 and the total number of MPs has climbed up to 119....   more»


TOP NEWS
VENTURE PHARM SERVICE--VPScro
»17/06/2009 [Company watch]
Venturepharm NASDAQ Flagship Commonwealth Biotechnologies, Inc. Announces Agreement to Acquire Largest Peptide Biotech Company in China

Venturepharm is pleased to inform that its NASDAQ flagship company, Commonwealth Biotechnologies, Inc, has executed an agreement to acquire all of the outstanding shares of a privately owned Shanghai-based chemical company...   more»


TOP NEWS
VENTURE PHARM SERVICE--VPScro
»24/07/2009 [Company watch]
AlphaRx Inc. (ALRX) Signs Cooperation Agreement with Venturepharm China

ChinaBio Today -- AlphaRx and Venturepharm China, a subsidiary of Venturepharm Laboratories Ltd., recently entered into a cooperation agreement. Venturepharm will provide AlphaRx with research services for its vaccine and anti-cancer drugs. Venturepharm will also help AlphaRx develop adjuvant vaccines for swine flu (A/H1N1)....   more»


VENTURE PHARM SERVICE--VPScro »05/08/2009 [Industry news]
AlphaRx, Venturepharm announce collaboration agreement

The goal of this is to enhance AlphaRxs research capabilities, expedite the development of new products as well as to expand the its product range....   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.